UMMS Affiliation
School of Medicine; Division of Hematology and Oncology, Department of Medicine
Publication Date
2021-02-25
Document Type
Article
Disciplines
Hematology | Hemic and Lymphatic Diseases | Immunotherapy | Neoplasms | Oncology
Abstract
Bacillus Calmette-Guerin (BCG) has been studied in various cancers for its immune modulation. Although the mechanism is yet to be completely understood, we do have positive experiences in many oncological cases. Hereby, we present a case of an 82-year-old male with acute myeloid leukemia (AML) post allogeneic Stem Cell Transplants (AlloSCT) as a salvage therapy, now in remission, who presented with hematuria. Workup confirmed non-muscle invasive Bladder Cancer (NMIBC), for which he was treated with nine sessions of intravesical BCG therapy. During BCG treatment, the patient developed gradually increasing lymphocyte counts. Flowcytometry of a peripheral blood sample showed polyclonal cell lymphocytosis with CD8+ T-cell expansion. Although further work up his lymphocytosis to be polyclonal, it has persisted at follow-up for the last 4 years. Also, we did not find any evidence of leukemia recurrence at follow-up prompting us to associate the BCG use for this patient and it is role as immunomodulation to keep AML disease in remission.
Keywords
cancer, bladder, leukemia, vaccine, immunity
Rights and Permissions
Copyright © 2021 Kennedy et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
DOI of Published Version
10.2147/IMCRJ.S296387
Source
Kennedy A, Sahu KK, Cerny J. Role of Immunomodulation of BCG Therapy on AML Remission. Int Med Case Rep J. 2021 Feb 25;14:115-119. doi: 10.2147/IMCRJ.S296387. PMID: 33658865; PMCID: PMC7920581. Link to article on publisher's site
Journal/Book/Conference Title
International medical case reports journal
Related Resources
PubMed ID
33658865
Repository Citation
Kennedy A, Sahu KK, Cerny J. (2021). Role of Immunomodulation of BCG Therapy on AML Remission. Open Access Publications by UMMS Authors. https://doi.org/10.2147/IMCRJ.S296387. Retrieved from https://escholarship.umassmed.edu/oapubs/4603
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial 3.0 License
Included in
Hematology Commons, Hemic and Lymphatic Diseases Commons, Immunotherapy Commons, Neoplasms Commons, Oncology Commons